Genome Sequencing: Understanding DNA Composition and Function

The human genome comprises approximately 3 billion base pairs of DNA, organised into 23 pairs of chromosomes.¹ Each base pair consists of two complementary nucleotides: adenine (A) with thymine (T), and guanine (G) with cytosine (C). The specific sequence of these base pairs encodes the genetic instructions necessary for an organism's development and function.¹ Scientists employ various methods to ascertain this sequence, with the primary goal being to read the order of A, T, C, and G along the DNA strands. This process, known as DNA sequencing, has evolved significantly since its inception.

Methods for Genomic Analysis

Early sequencing methods, such as Sanger sequencing (also known as the chain-termination method), were foundational. This technique involves creating DNA copies using modified nucleotides that terminate the replication process at specific bases.² The resulting fragments, varying in length, are then separated by size, allowing the original sequence to be inferred. While highly accurate for shorter DNA segments, Sanger sequencing is labour-intensive and not practical for sequencing an entire genome.²

The advent of next-generation sequencing (NGS) technologies, also termed high-throughput sequencing, revolutionised genomic analysis. These methods enable the parallel sequencing of millions of DNA fragments simultaneously.³ A common NGS approach involves fragmenting the entire genome into smaller pieces, typically 100-500 base pairs in length.³ These fragments are then ligated with adapter sequences and immobilised on a solid surface, such as a flow cell. Each fragment is amplified to create clusters of identical DNA molecules. Fluorescently labelled nucleotides are then added, and a camera captures the light emitted as each nucleotide is incorporated into the growing DNA strand.³ This parallel process generates vast amounts of sequence data, which bioinformatic tools then align and assemble to reconstruct the original genomic sequence.⁴

Different NGS platforms exist, each with specific advantages regarding read length, accuracy, and cost. Whole-genome sequencing (WGS) aims to sequence the entire genome, providing comprehensive information about both coding and non-coding regions.⁵ In contrast, whole-exome sequencing (WES) focuses specifically on the exome, which comprises the protein-coding regions of the genome and accounts for approximately 1-2% of the total genome.⁵ WES is often preferred in clinical settings for identifying disease-causing mutations because most known pathogenic variants reside within exons.⁵ Targeted sequencing, another approach, focuses on specific genes or regions of interest, offering higher depth of coverage and cost-effectiveness for known genetic conditions.⁶

The data generated from sequencing requires sophisticated computational analysis. Bioinformatic pipelines are used to quality control the raw sequence reads, align them to a reference genome, identify variants (such as single nucleotide polymorphisms (SNPs), insertions, and deletions), and interpret their potential functional consequences.⁴ The accuracy of these analyses is paramount for clinical utility, with variant calling algorithms continually being refined to minimise false positives and false negatives.⁴

The clinical utility of genome sequencing is rapidly expanding. In oncology, WGS and WES can identify somatic mutations in tumours, guiding targeted therapies and predicting treatment response. For rare genetic diseases, sequencing can provide a definitive diagnosis, ending diagnostic odysseys and enabling personalised management strategies. Preimplantation genetic testing (PGT) and prenatal diagnosis also leverage sequencing to detect chromosomal abnormalities or monogenic disorders.

Despite its transformative potential, genome sequencing faces limitations. The interpretation of variants of uncertain significance (VUS) remains a significant challenge, often requiring further functional studies or family segregation analysis. Ethical considerations surrounding data privacy, informed consent, and the potential for incidental findings also necessitate careful navigation. Furthermore, the cost of sequencing, while decreasing, can still be a barrier to widespread adoption, particularly in resource-limited settings.

Future Directions in Genomic Medicine

The future of genome sequencing is poised for further innovation. Long-read sequencing technologies, such as Pacific Biosciences (PacBio) and Oxford Nanopore Technologies, are gaining prominence. These methods can sequence much longer DNA fragments, improving the detection of structural variants, repetitive regions, and complex rearrangements that are often missed by short-read NGS. 7 The integration of multi-omics data – including genomics, transcriptomics, proteomics, and metabolomics – promises a more holistic understanding of disease mechanisms. Artificial intelligence and machine learning algorithms are also being developed to enhance variant interpretation, predict disease risk, and personalise treatment recommendations, ultimately moving towards a truly predictive, preventive, personalised, and participatory (P4) medicine.